Educating Medical Professionals for that “Rare Encounter”
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.
This Webinar series explores the fundamental concept of big data in Medical Affairs, from which sources can we retrieve this, what are the broader considerations when utilizing data in health and what impact this can have on our organizations, physicians, and patients, now and in the future.
This Webinar series explores how roles and talent management have evolved, what new roles exist or are needed and what skills and competencies are required to succeed in these roles. From the manager’s perspective, we will discuss potential strategies for staying on top of this ever-changing field to manage and retain highly effective teams.
This article provides top-level framework and broad conceptual categories for understanding digital structures within Medical Affairs and biopharmaceutical/MedTech organizations, helping leaders to make organizational decisions to drive their digital strategy with intention and purpose.
In 2022, organizations gained ground in patient trust, decentralized clinical trials, virtual tools, and diverse conversations throughout the product development process. So – now what?
This White Paper provides a foundational understanding of insights management, including the definition and value of insights, processes and technologies for insights management, and key challenges in implementation.
In this our third episode this season, we’ll be discussing how and why medical publishing is changing and where is it going in the future.
With a multibillion dollar investment from Microsoft and already 4 authorship credits on PubMed, ChatGPT is poised to disrupt Medical Affairs.
This presentation looks at different regulatory contexts in which product developers are using RWE.
2023 brings increased expectations from the FDA for patient-focused drug development (PFDD). Medical Affairs organizations need to develop new skills to put the patient voice at the center of drug, device, and diagnostic development and evaluation.